MOHAMMAD AZAB
CIK 1309653 · Chief Medical Officer · last filed 2026-01-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.94M
Companies
5
Total Filings
42
Lifetime Open-Market Net
$104.7K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LSTA | Director | 104,925 | $1.16 | $121.7K | $0 | 5 | 2026-01-13 |
| DURECT CORP (DRRX) Delisted | Director | 0 | $1.91 | $0 | $23.8K | 8 | 2025-09-12 |
| XENE | Director | 74,225 | $64.94 | $4.82M | $80.9K | 23 | 2023-12-20 |
| ASTX | Chief Medical Officer | — | $10.14 | — | $0 | 2 | 2012-12-10 |
| Astex Pharmaceuticals, Inc (SUPG) Delisted | Chief Medical Officer | — | — | — | $0 | 3 | 2011-03-28 |
Recent Filings · Page 4 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-12-02 | XENE | Mixed | +7,937 | $5.2K | EDGAR |
| 2016-06-03 | XENE | Grant (A) | — | $0 | EDGAR |
| 2015-12-14 | XENE | Exer (M) | +2,469 | $12.9K | EDGAR |
| 2015-05-06 | XENE | Grant (A) | — | $0 | EDGAR |
| 2015-01-12 | XENE | Exer (M) | +2,469 | $12.3K | EDGAR |
| 2014-11-06 | XENE | Grant (A) | — | $0 | EDGAR |
| 2013-10-16 | — | Mixed | −8,753 | $0 | |
| 2012-12-10 | ASTX | Grant (A) | — | $0 | EDGAR |
| 2012-03-09 | ASTX | Grant (A) | — | $0 | EDGAR |
| 2011-03-28 | Astex Pharmaceuticals, Inc (SUPG) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.